文章目录

英国普罗赛罗研究

原文发布日期：2022-03-24

英文摘要：

摘要翻译：

原文链接：

文章：

英国普罗赛罗研究

UK PROSECO study

原文发布日期：2022-03-24

英文摘要：

Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. Here we present the PROSECO prospective observational study (NCT04858568) on 457 patients with lymphoma that received two or three COVID-19 vaccine doses. We show undetectable humoral responses following two vaccine doses in 52% of patients undergoing active anticancer treatment. Moreover, 60% of patients on anti-CD20 therapy had undetectable antibodies following full vaccination within 12 months of receiving their anticancer therapy. However, 70% of individuals with indolent B-cell lymphoma displayed improved antibody responses following booster vaccination. Notably, 63% of all patients displayed antigen-specific T-cell responses, which increased after a third dose irrespective of their cancer treatment status. Our results emphasize the urgency of careful monitoring of COVID-19-specific immune responses to guide vaccination schemes in these vulnerable populations.

摘要翻译：

血液学恶性肿瘤患者由于免疫力下降存在严重新冠肺炎结果增强的风险，但现有研究中由于研究设计的内在局限性导致了研究结论的可靠性受到限制。在此，我们介绍了PROSECO前瞻性观察性研究（NCT04858568），该研究涉及接种两到三剂新冠疫苗的淋巴瘤患者457例。结果显示，在接受活跃抗癌治疗的患者中，两个新冠疫苗剂量后出现抗体检测不到的情况的比例为52%。此外，在接受了全剂量抗CD20治疗的患者中，有60%在接种完疫苗12个月内抗体仍未检测到。然而，在惰性B细胞淋巴瘤患者中，70%的个体在加强针接种后抗体反应有所改善。值得注意的是，所有患者的T细胞反应情况为63%，这种反应在第三剂接种后会增加，无论其是否接受过癌治疗。我们的研究结果强调了对新冠特定免疫反应仔细监测的重要性，以便指导针对易感人群的疫苗方案制定。